中文
EN
About us
Company Introduction
Corporate History
Business Introduction
Corporate Governance
Company Culture
Corporate Honors
R&D and Innovation
R&D System and Platforms
Innovation Strategy
Innovation Pipeline
Achievements
Products
Drug Products
Next-gen Therapies
APIs
Boranes
Services
CDMO
Project Collaboration
In-/Out-Licensing
Joint Venture
Sustainable
EHS
Energy
Quality
Supplier
News Center
2026
2025
2024
2023
2022
2021
Join Us
Talent Philosophy
Talent Development
Salary and Benefits
Campus Recruiting
Social Recruitment
Contact Us
Online Message
Blog Center
In 2026
In 2025
In 2024
In 2023
In 2022
In 2021
In 2020
In 2019
In 2018
In 2017
In 2016
Viwit 2025 Annual Shareholders’ Meeting Successfully Concluded | Focus on Innovation, Steady Progress
39th World No Tobacco Day | Smoke-Free Youth, Boundless Future — Science-Based Smoking Cessation Makes Health and Future Accessible
Viwit’s Video “Ten Years in China, Growing with Viwit” Wins Second Prize in 2025 Shandong Province Foreign Expert Video Competition
Viwit Wins JD.com “Innovation Marketing Award” | Dr. Keene Wei Invited to JD Health 10th Anniversary & 2026 JD Pharmacy Partner Conference
Dr. Keene Wei Named “Outstanding Entrepreneur” by Both Tengzhou City and Zaozhuang High-Tech Zone
Dr. Keene Wei Invited as Keynote Speaker at His Alma Mater Dartmouth College’s Dreyfus Lecture, Showcasing Chinese Pharmaceutical Innovation
Viwit Pharmaceuticals' Gadoterate Meglumine Injection Receives Official Approval by China NMPA
Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for their Gadoterate Meglumine Injection. This approval includes the following strengths: 10 mL containing 3.769 g, 15 mL containing 5.654 g, and 20 mL containing 7.538 g. The corresponding approval numbers are H20243899, H20243900, and H20243901.
17
/
06
Viwit Pharmaceuticals' Deslanoside Injection Receives Official Approval by China NMPA
May 8, 2024 – Viwit Pharmaceuticals proudly announces the receipt of the "Drug Supplementary Application Approval Notice" from the National Medical Products Administration (NMPA) for the drug product, Deslanoside Injection. The approval notice number is 2024B01980.
15
Viwit’s Levetiracetam Tablets Approved by FDA
On April 5, 2024, Viwit Pharmaceuticals' Levetiracetam Tablets received an Approval Letter (#078869) from the U.S. Food and Drug Administration (FDA), marking Viwit's first approved oral solid dosage in the United States.
09
04
Viwit Pharmaceuticals' Mirabegron API Receives Official Approval by China NMPA
On January 23, 2024, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for its own proprietary active pharmaceutical ingredient (API) Mirabegron, developed independently. The issued registration number is Y20220000096, and the corresponding notice number is 2024YS00039.
26
01
Viwit Pharmaceuticals' Vildagliptin Tablets Receive Official Approval by China NMPA
Viwit Pharmaceuticals is pleased to announce the acquisition of the Drug Registration Certificate (Certificate No: 2023S01974) from the National Medical Products Administration (NMPA) for a proprietary finished dosage form, Vildagliptin tablet. This signifies the official approval of this product in the Chinese market.
22
12
Viwit Pharmaceuticals' Lidocaine Injection Receives Official Approval by China NMPA
On December 18, 2023, Viwit Pharmaceuticals received the "Drug Supplementary Application Approval Notice" (Notice No: 2023B06224) issued by the China National Medical Products Administration for a proprietary finished dosage form, Lidocaine Hydrochloride for Injection (5ml: 0.1g).
19
Viwit Pharmaceuticals' Vildagliptin API Receives Official Approval by China NMPA
On November 30, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by National Medical Products Administration (NMPA) for its independently developed active pharmaceutical ingredient (API), Vildagliptin. The registration number is Y20210000619, and the notice number is 2023YS00803.
07
Viwit Pharmaceuticals' Aprepitant API Receives Official Approval by China NMPA
On October 26, 2023, Viwit Pharmaceuticals received the "Notice of Approval of Application for Listing of Chemical APIs" issued by China National Medical Products Administration (NMPA) for the independently developed active pharmaceutical ingredient (API) Aprepitant. The registration number is Y20210000473, and the notice number is 2023YS00727.
31
10
Search
中文
EN
